INFECTIOUS ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTIANGIOGENIC AGENTS
- 1 May 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Retina
- Vol. 29 (5), 601-605
- https://doi.org/10.1097/iae.0b013e31819d2591
Abstract
To evaluate the rate of infectious endophthalmitis associated with intravitreal injection of bevacizumab, ranibizumab, and pegaptanib sodium. A retrospective review of patients who received intravitreal injections of bevacizumab, ranibizumab, and pegaptanib sodium was undertaken. Cases of clinical diagnoses of endophthalmitis or suspected endophthalmitis resulting from intravitreal injection were identified and reviewed. From these data, the risk per injection was estimated. Three patients developed endophthalmitis after the intravitreal injection. The risk per injection was 0.00077 (0.077%). The rate of endophthalmitis was 1 per 1,291 injections. A similar risk of endophthalmitis per injection compared with some trials was obtained in this study. Although no definite risk factors could be identified, intravitreal injections performed by nonretina specialist physicians may be a risk factor for the development of endophthalmitis.Keywords
This publication has 22 references indexed in Scilit:
- Aktuelle therapeutische Möglichkeiten bei der neovaskulären altersabhängigen MakuladegenerationDer Ophthalmologe, 2007
- Topical Antibiotic Prophylaxis in Intraocular InjectionsAmerican Journal of Ophthalmology, 2007
- Infectious and Noninfectious Endophthalmitis After Intravitreal BevacizumabJournal of Ocular Pharmacology and Therapeutics, 2007
- Reducing the Risk of Endophthalmitis Following Intravitreal InjectionsRetina, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab: Phase III Clinical Trial ResultsPublished by Dougmar Publishing Group, Inc. ,2006
- Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: A Phase I/II Multicenter, Controlled, Multidose StudyOphthalmology, 2006
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004
- RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEWRetina, 2004